Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain.

Abstract:

:A nephropathogenic K2/01 strain of infectious bronchitis virus (IBV) was attenuated by 170 serial passages in embryonated chicken eggs for possible use as a future IBV vaccine strain. High-growth properties and narrow tissue tropisms (limited replication in respiratory tracts) were achieved by the adaptation process. Unlike the parent strain, the attenuated strain (K2p170) was safe in day-old specific-pathogen-free chicks since replication of the virus did not induce mortality and nephritis, and rarely induced histological changes in the trachea and kidney after intraocular administration. In day-old broilers, even though coarse spray administration of K2p170 induced clinical signs, ciliostasis, and histopathological lesions in the trachea and the kidney, they were all comparable to birds vaccinated with commercial H120 vaccine. Despite restriction of viral replication in the respiratory tract, K2p170 elicited the production of antiserum with a neutralization index of 4.5. K2p170 provided almost complete protection against both two distinct subgroups of Korean nephropathogenic strain (KM91-like and QX-like subgroup). Furthermore, K2p170 provided significantly greater cross-protection against two heterologous strains (Massachusetts and Korean respiratory strain) than those conferred by the commercial H120 vaccine. K2p170 also had no virulence reversion after five back passages in chickens. In conclusion, K2p170 exhibits a fine balance between attenuation and immunogenicity, possesses cross-protective efficacy, and merits further investigation as a potential live vaccine as an alternative means of protection against the recently emergent nephropathogenic IBV infection in many Eurasian countries.

journal_name

Vaccine

journal_title

Vaccine

authors

Lee HJ,Youn HN,Kwon JS,Lee YJ,Kim JH,Lee JB,Park SY,Choi IS,Song CS

doi

10.1016/j.vaccine.2010.01.062

subject

Has Abstract

pub_date

2010-04-01 00:00:00

pages

2887-94

issue

16

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(10)00138-6

journal_volume

28

pub_type

杂志文章

相关文献

VACCINE文献大全
  • fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.

    abstract::Meningococci bind human fH to down-regulate complement, which enhances survival of the bacteria in serum. A major fH ligand is the vaccine candidate, factor H-binding protein (fHbp). Although fHbp has been considered an essential meningococcal virulence factor, rarely, invasive isolates with absent fHbp genes or frame...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.06.009

    authors: Giuntini S,Vu DM,Granoff DM

    更新日期:2013-08-28 00:00:00

  • Proteomic analysis of influenza haemagglutinin-specific antibodies following vaccination reveals convergent immunoglobulin variable region signatures.

    abstract::Analysis of the anti-haemagglutinin serum antibody proteome from six H1N1pdm09 influenza A vaccinated subjects demonstrated restricted IgG1 heavy chain species encoded by IGHV5-51 and IGHV3-7 gene families in 2 subjects and either IGHV5-51 or IGHV3-7 in 4 individuals. All subjects exhibited a dominant IGKV3-20 light c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.08.053

    authors: Adamson PJ,Al Kindi MA,Wang JJ,Colella AD,Chataway TK,Petrovsky N,Gordon TP,Gordon DL

    更新日期:2017-10-09 00:00:00

  • Immunogenicity and protection conferred by an optimized purified inactivated Zika vaccine in mice.

    abstract::After decades of inconsequential infections, and sporadic outbreaks in the Asia-Pacific region between 2007 and 2013, Zika virus caused a widespread epidemic in South America in 2015 that was complicated by severe congenital infections. After the WHO declared a Public Health Emergency of International Concern in Febru...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.04.013

    authors: Lecouturier V,Bernard MC,Berry C,Carayol S,Richier E,Boudet F,Heinrichs J

    更新日期:2019-05-06 00:00:00

  • Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country.

    abstract:BACKGROUND:Most developing countries are implementing the WHO immunisation programme. Although vaccines reach most children, many modifications of the recommended schedule are observed in practice. We investigated the association between vaccination status and risk of hospitalisation in Guinea-Bissau. METHODS:From May...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.03.016

    authors: Biai S,Rodrigues A,Nielsen J,Sodemann M,Aaby P

    更新日期:2011-05-09 00:00:00

  • Severe thrombocytopenia after hepatitis B vaccine in an infant from Turkey.

    abstract::Recombinant hepatitis B vaccine has been used widely in the world since 1991. The side effects of hepatitis B vaccine are seen rarely. In this paper, we present clinical and laboratory progress of an infant who gets severe thrombocytopenia after the second dosage hepatitis B vaccine. Our case is different from other c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.09.062

    authors: Polat A,Akca H,Dagdeviren E

    更新日期:2008-12-02 00:00:00

  • Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.

    abstract::SPf66 is the first chemically synthesised vaccine to elicit a partial protective immune response against malaria. The aluminium hydroxide (alum)-adsorbed SPf66 vaccine is weakly immunogenic and of poor to moderate efficacy in humans. To investigate the possibility of improving SPf66 vaccine immunogenicity, a delivery ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00192-x

    authors: Rosas JE,Hernández RM,Gascón AR,Igartua M,Guzman F,Patarroyo ME,Pedraz JL

    更新日期:2001-08-14 00:00:00

  • Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia.

    abstract:OBJECTIVES:The objectives of this study were to estimate the national prevalence of hepatitis B infection in Tunisia using data from a nationwide survey, to compare results with those obtained in 1996 survey and to evaluate the impact of vaccination twenty years after its introduction. METHODS:A National household-bas...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.08.038

    authors: Ben Hadj M,Bouguerra H,Saffar F,Chelly S,Hechaichi A,Talmoudi K,Bahrini A,Chouki T,Hazgui O,Hannachi N,Letaief H,Bellali H,Bahri O,Ben-Alaya-Bouafif N

    更新日期:2018-09-18 00:00:00

  • Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.

    abstract::Different subsets of dendritic cells (DC) elicit qualitatively different immune responses. In mice, two lymphoid tissue-resident subsets, CD8α(+) and CD8α(-), have been implicated in the induction of T helper 1 (Th1) or Th2 responses, respectively. Moreover, CD8α(+) DC appear to play a major role in priming CD8(+) T l...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.06.071

    authors: Suleman M,Galea S,Gavard F,Merillon N,Klonjkowski B,Tartour E,Richardson J

    更新日期:2011-08-11 00:00:00

  • Gene expression profiling toward the next generation safety control of influenza vaccines and adjuvants in Japan.

    abstract::Influenza becomes epidemic worldwide every year, and many individuals receive vaccination annually. Quality control relating to safety and potency of influenza vaccines is important to maintain public confidence. The safety of influenza vaccines has been assessed by clinical trials, and animal safety tests are perform...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.09.021

    authors: Momose H,Sasaki E,Kuramitsu M,Hamaguchi I,Mizukami T

    更新日期:2018-10-15 00:00:00

  • HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis.

    abstract::The conventional treatment for paracoccidioidomycosis, the most prevalent mycosis in Latin America, involves long periods of therapy resulting in sequels and high frequency of relapses. The search for new alternatives of treatment is necessary. Previously, we have demonstrated that the hsp65 gene from Mycobacterium le...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.11.062

    authors: Ribeiro AM,Bocca AL,Amaral AC,Souza AC,Faccioli LH,Coelho-Castelo AA,Figueiredo F,Silva CL,Felipe MS

    更新日期:2010-02-10 00:00:00

  • Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.

    abstract::The carbohydrate moieties on HIV-1 envelope glycoprotein (Env) act as shields to mask conserved neutralizing epitopes, while the hyperimmunogenic variable regions are immunodominant in inducing non-neutralizing antibodies, representing the major challenge for using Env as a vaccine candidate to induce broadly neutrali...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.09.073

    authors: Fu M,Hu K,Hu H,Ni F,Du T,Shattock RJ,Hu Q

    更新日期:2019-12-03 00:00:00

  • pH-sensitive carbonate apatite nanoparticles as DNA vaccine carriers enhance humoral and cellular immunity.

    abstract::To demonstrate the potential of pH-sensitive carbonate apatite (CO₃Ap) nanoparticles as DNA vaccine carriers to enhance vaccination efficacy, we examined the humoral and cellular immune responses of C57BL/6 mice immunized with the plasmid expression vector pCI-neo encoding the full-length soluble ovalbumin (OVA) (pCI-...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.09.032

    authors: He P,Takeshima SN,Tada S,Akaike T,Ito Y,Aida Y

    更新日期:2014-10-29 00:00:00

  • An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.

    abstract::To test whether inactivated influenza vaccines distributed during the 2003-2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three in...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.01.015

    authors: Del Giudice G,Hilbert AK,Bugarini R,Minutello A,Popova O,Toneatto D,Schoendorf I,Borkowski A,Rappuoli R,Podda A

    更新日期:2006-04-12 00:00:00

  • The purification and protective capacity of Bordetella pertussis outer membrane proteins.

    abstract::The whole cell vaccine (WCV) of Bordetella pertussis is protective in the intracerebral (i.c.) mouse protection assay. We found a correlation between the i.c. mouse protection assay potency and the presence of the virulence-associated outer membrane proteins (OMPs) in outer membrane complexes (OMC). The virulence-asso...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)00040-t

    authors: Hamstra HJ,Kuipers B,Schijf-Evers D,Loggen HG,Poolman JT

    更新日期:1995-01-01 00:00:00

  • Development of lactococcal GEM-based pneumococcal vaccines.

    abstract::We report the development of a novel protein-based nasal vaccine against Streptococcus pneumoniae, in which three pneumococcal proteins were displayed on the surface of a non-recombinant, killed Lactococcus lactis-derived delivery system, called Gram-positive Enhancer Matrix (GEM). The GEM particles induced the produc...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.026

    authors: Audouy SA,van Selm S,van Roosmalen ML,Post E,Kanninga R,Neef J,Estevão S,Nieuwenhuis EE,Adrian PV,Leenhouts K,Hermans PW

    更新日期:2007-03-22 00:00:00

  • Oral administration of myostatin-specific whole recombinant yeast Saccharomyces cerevisiae vaccine increases body weight and muscle composition in mice.

    abstract::Myostatin negatively regulates skeletal muscle growth. It was found that active immunization with myostatin-specific vaccine blocked myostatin function in vivo, which resulted in increase of body weight and muscle composition in mice. However, traditional vaccine and its administration method are expensive and laborio...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.08.007

    authors: Zhang T,Yang H,Wang R,Xu K,Xin Y,Ren G,Zhou G,Zhang C,Wang L,Zhang Z

    更新日期:2011-10-26 00:00:00

  • Penton-dodecahedron of fowl adenovirus serotype 4 as a vaccine candidate for the control of related diseases.

    abstract::In some serotypes of adenovirus (Ad), the penton base and attached trimeric fiber assemble into dodecameric virus-like particles called penton-dodecahedron (Pt-Dd), which can be internalized and used to deliver the vaccine antigens and drugs. Fowl adenovirus serotype 4 (FAdV-4) is an important pathogen, causing seriou...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.12.041

    authors: Wang X,Tang Q,Qiu L,Yang Z

    更新日期:2019-02-04 00:00:00

  • Vaccination of sheep with Quil-A® adjuvant expands the antibody repertoire to the Fasciola MF6p/FhHDM-1 antigen and administered together impair the growth and antigen release of flukes.

    abstract::Fasciolosis continues to be a major cause of economic losses in the livestock industry and a growing threat to humans. The limited spectrum of effective anthelmintics and the appearance of resistances urge the need for developing an effective vaccine. Most studies have been focused on the use of TH1-polarizing adjuvan...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.02.115

    authors: Orbegozo-Medina RA,Martínez-Sernández V,González-Warleta M,Castro-Hermida JA,Mezo M,Ubeira FM

    更新日期:2018-04-05 00:00:00

  • Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

    abstract::A conjugate vaccine against meningococcus A and C was prepared using the non-toxic mutant of diphtheria toxin CRM 197 as a carrier protein. Capsular polysaccharides of Neisseria meningitidis group A and C were hydrolysed and the resulting oligosaccharides were then coupled to CRM 197 in order to obtain conjugates with...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/0264-410x(92)90091-w

    authors: Costantino P,Viti S,Podda A,Velmonte MA,Nencioni L,Rappuoli R

    更新日期:1992-01-01 00:00:00

  • GM-CSF-surface-modified B16.F10 melanoma cell vaccine.

    abstract::Through the specific and tight interaction between streptavidin and biotin, a novel platform was developed to allow for rapid (less than 2h), efficient and durable display of streptavidin-tagged bioactive GM-CSF on the surface of biotinylated B16.F10 tumor cells. This technology involved biotinylation of the cell memb...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.031

    authors: Gao J,Huang S,Li M,Luo R,Wang X,Takashima A

    更新日期:2006-06-19 00:00:00

  • A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

    abstract::A randomized, double-blind trial comparing a diphtheria-tetanus-acellular pertussis vaccine (DTaP) (pertussis toxoid and filamentous hemagglutinin) with a whole-cell vaccine (DTwP) was conducted. A case-contact study was nested in the trial to estimate absolute efficacy. From 1990 through 1994, 4181 children were rand...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0264-410x(97)00100-x

    authors: Simondon F,Preziosi MP,Yam A,Kane CT,Chabirand L,Iteman I,Sanden G,Mboup S,Hoffenbach A,Knudsen K,Guiso N,Wassilak S,Cadoz M

    更新日期:1997-10-01 00:00:00

  • Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.

    abstract::On February 17-18, 2010, the World Health Organization (WHO) convened the 6th meeting on the "Evaluation of pandemic influenza vaccines in clinical trials" to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were revie...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.07.034

    authors: Girard MP,Katz J,Pervikov Y,Palkonyay L,Kieny MP

    更新日期:2010-10-04 00:00:00

  • Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.

    abstract::The development of live attenuated vaccines, allowing for the safe and effective immunisation at mucosal surfaces, is a strategy of great interest for vaccinologists. The main advantage of this approach over conventional parenteral vaccines is the induction of strong mucosal immune responses, allowing targeting of the...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2003.12.033

    authors: Viret JF,Dietrich G,Favre D

    更新日期:2004-06-23 00:00:00

  • The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination.

    abstract::Anti-tumor vaccination is being evaluated as a prophylactic and therapeutic strategy against cancer growth, dissemination (spreading) or recurrence. Although a large number of studies investigate in detail the identity of antigens to be used for efficacious immune intervention, there have been few studies investigatin...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.03.073

    authors: Parvanova I,Rettig L,Knuth A,Pascolo S

    更新日期:2011-05-17 00:00:00

  • Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.

    abstract::The neuraminidase (NA) protein of influenza A viruses (IAV) has important functional roles in the viral replication cycle. Antibodies specific to NA can reduce viral replication and limit disease severity, but are not routinely measured. We analyzed NA inhibiting (NI) antibody titers in serum and respiratory specimens...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.06.001

    authors: Sandbulte MR,Gauger PC,Kitikoon P,Chen H,Perez DR,Roth JA,Vincent AL

    更新日期:2016-07-19 00:00:00

  • Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice.

    abstract::In a study to develop novel vaccination strategies against tuberculosis, we encapsulated DNA encoding Ag85B, MPT-64 and MPT-83 antigens mixed with dimethyldioctyldecyl ammonium bromide (DDA) into biodegradable poly(dl-lactide-co-glycolide, PLGA) microspheres. Scanning electron microscopy (SEM) analysis demonstrated a ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.03.024

    authors: Cai H,Hu XD,Yu DH,Li SX,Tian X,Zhu YX

    更新日期:2005-07-14 00:00:00

  • Safe vaccination of children with a virosomal adjuvanted influenza vaccine.

    abstract::A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardia...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.12.008

    authors: Künzi V,Dornseiff M,Horwath J,Hartmann K

    更新日期:2009-02-18 00:00:00

  • An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.

    abstract::Yellow fever is an acute infectious disease caused by prototype virus of the genus Flavivirus. It is endemic in Africa and South America where it represents a serious public health problem causing epidemics of hemorrhagic fever with mortality rates ranging from 20% to 50%. There is no available antiviral therapy and v...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.03.077

    authors: Pereira RC,Silva AN,Souza MC,Silva MV,Neves PP,Silva AA,Matos DD,Herrera MA,Yamamura AM,Freire MS,Gaspar LP,Caride E

    更新日期:2015-08-20 00:00:00

  • Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).

    abstract::The hepatitis E virus (HEV) vaccine, Hecolin(®), was licensed in China for the prevention of HEV infection and HEV-related diseases with demonstrated safety and efficacy [1,2]. The vaccine is composed of a truncated HEV capsid protein, p239, as the sole antigen encoded by open reading frame 2 and produced using Escher...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.05.064

    authors: Zhang X,Wei M,Pan H,Lin Z,Wang K,Weng Z,Zhu Y,Xin L,Zhang J,Li S,Xia N,Zhao Q

    更新日期:2014-07-07 00:00:00

  • Immunization with PfEMP1-DBL1alpha generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes.

    abstract::A family of parasite antigens known as Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is believed to play an important role in the binding of infected erythrocytes to host receptors in the micro-vasculature. Available data advocates the existence of a subset of very adhesive (rosetting, auto-agglutinati...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.02.015

    authors: Chen Q,Pettersson F,Vogt AM,Schmidt B,Ahuja S,Liljeström P,Wahlgren M

    更新日期:2004-07-29 00:00:00